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Abstract Lipopolysaccharide endotoxin and interferon-Q in-
duced inducible nitric oxide synthase (iNOS) protein expression
and nitrite/nitrate formation in microvascular endothelial cell
cultures (ECs) derived from rat skeletal muscle. Pretreatment of
ECs with ascorbate accumulated a large amount of ascorbate
inside the cells and consequently decreased both intracellular
oxidant level and iNOS induction. These effects of ascorbate
were abolished in the presence of exogenous superoxide
generated by xanthine oxidase/xanthine plus catalase but were
not altered when N-nitro-L-arginine methyl ester was applied to
inhibit nitric oxide synthesis. Ascorbate also attenuated the
activation of transcription factor IRF-1 but not NFUB. These
results indicate that ascorbate inhibits iNOS expression in ECs
by an antioxidant mechanism independent of both NFUB
activation and the reported negative feedback effect of nitric
oxide. , 2002 Published by Elsevier Science B.V. on behalf of
the Federation of European Biochemical Societies.
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1. Introduction
As part of the systemic in£ammatory response in sepsis,
induction of inducible nitric oxide synthase (iNOS) by endo-
toxin (lipopolysaccharide, LPS) and in£ammatory cytokines
(e.g. interferon-Q, IFNQ) contributes to the bactericidal e¡ects
of phagocytes [1,2]. LPS and cytokines also induce iNOS in
vascular endothelial cells (ECs) and smooth muscle cells; this
induction is at least partially responsible for vascular hypo-
reactivity, hypotension and subsequent multiple organ failure
[3,4]. Development of highly selective iNOS inhibitors for
sepsis treatment has been fraught with di⁄culties and has
not yielded the bene¢ts expected [5,6]. Nevertheless, the pro-
cess of iNOS induction remains a promising target for sepsis
therapy.
Reactive oxygen species, superoxide in particular, have been
implicated in the potentiation of iNOS induction in ECs and
other cell types [7^9]. Depletion of the endogenous antioxi-
dant ascorbate occurs during sepsis [10,11] and may sensitize
cells to stimuli that induce iNOS. Recently, ascorbate admin-
istration was found to prevent the decrease of blood pressure
and the maldistribution of capillary blood £ow in skeletal
muscle of septic rats [11]. These e¡ects of ascorbate could
have been mediated via inhibition of iNOS expression. The
present study used microvascular ECs of rat skeletal muscle
origin to evaluate the hypothesis that the antioxidant activity
of ascorbate may prevent iNOS induction in ECs stimulated
by LPS+IFNQ.
2. Methods
2.1. ECs from skeletal muscle
Microvascular ECs were isolated from the male Wistar rat extensor
digitorum longus muscle using a cell-trapping technique as described
by us [9]. ECs were cultured in medium M199 (Sigma, St. Louis, MO,
USA; all chemical agents used in the current study were obtained
from Sigma except those otherwise indicated) supplemented with
10% heat-inactivated fetal bovine serum (Life Technologies, Grand
island, NY, USA), 2 mM L-glutamine, 100 U/ml penicillin, 100 Wg/
ml streptomycin, 30 Wg/ml EC growth supplement (Collaborative Bio-
medical, Bedford, MA, USA) in a standard CO2 incubator. EC iden-
ti¢cation was carried out as described by our laboratory [12]. Experi-
ments were performed using con£uent monolayers (passages three
through eight) originating from at least three di¡erent rats for each
experiment. ECs were treated with various agents (dissolved in the
culture medium, i.e. the vehicle) as described in detail in ¢gure
legends.
2.2. Measurement of intracellular ascorbate
Ascorbate concentrations in ECs were assayed by acidic extraction
and HPLC with electrochemical detection, according to a procedure
described previously by us [13].
2.3. Measurement of nitrate and nitrite (NOx)
NOx content in the culture medium was measured to estimate the
total nitric oxide (NO) production of cultured cells. An aliquot of the
medium was ¢ltered through a 10 000 Da molecular weight cuto¡
¢lter to eliminate proteins. Nitrate was converted to nitrite by nitrate
reductase. Total nitrite was then measured using a total NO assay kit
(Cayman, Ann Arbor, MI, USA). Brie£y, the reduced sample was
mixed with an equal volume of Griess reagent, and the absorbance
at 545 nm was measured immediately. The NOx concentration was
determined by comparison to a standard curve based on serial dilu-
tion of a sodium nitrate standard. The standard curve was linear over
a range of 3^50 WM (r=0.998).
2.4. Western blot analysis
iNOS protein expression in ECs was determined by Western blot as
previously described by us [9].
2.5. Measurement of intracellular oxidants
The intracellular oxidant levels in ECs were measured using dihy-
drorhodamine 123 (DHR123, Molecular Probes, Eugene, OR, USA),
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an oxidant-sensitive £uorochrome, according to a procedure described
in our previous study [9].
2.6. Nuclear extracts and electrophoretic mobility shift assay (EMSA)
Nuclear extracts of ECs were prepared as described previously [9].
For EMSA assay, double-stranded consensus oligonucleotides were
end-labeled with [Q-32P]ATP (Amersham Biosciences, Piscataway,
NJ, USA) and T4 polynucleotide kinase (MBI Fermentas, Flambor-
ough, ON, Canada). The sense sequences of oligoneleotides used were
IRF-1 (5P-GGA AGC GAA AAT GAA ATT GAC T-3P) and NFUB
(5P-AGT TGA GGG GAC TTT CCC AGG C-3P) (Santa Cruz Bio-
technology, Santa Cruz, CA, USA). The binding reaction was carried
out as described previously [9]. IRF-1 and NFUB oligonucleotide
speci¢city was veri¢ed by competition binding assay and supershift
assay as described by us [9].
2.7. Data analysis
Data were expressed as meanSS.E.M. values. Statistical analysis
was performed by one-way analysis of variance (ANOVA) followed
by a two-tailed Student t-test. Probabilities of P6 0.05 were consid-
ered signi¢cant.
3. Results
3.1. Ascorbate pretreatment accumulates ascorbate inside ECs
As shown in Fig. 1, non-preloaded ECs had undectable
ascorbate while pretreatment of ECs with ascorbate for 24 h
accumulated a substantial amount of ascorbate inside the
cells. Assuming a cell water content of 4 Wl/mg protein [12],
the intracellular concentration of ascorbate was 5.3 S 0.2 mM.
The intracellular ascorbate was signi¢cantly decreased 6 h
after the cells were transferred to ascorbate-free medium
(bars 3 vs. 2) but was still markedly higher than in non-pre-
loaded ECs (bars 3 vs. 1). Further, comparing the data at 6 h
with that at 12 h after removal of extracellular ascorbate
(bars 3 vs. 5) shows that intracellular ascorbate concentration
decreased slowly between 6 and 12 h time points. LPS+IFNQ
treatment did not change the intracellular concentration of
ascorbate (bars 4 vs. 3 and bars 6 vs. 5), indicating that
LPS+IFNQ did not cause ascorbate depletion.
3.2. Ascorbate pretreatment inhibits iNOS induction
Fig. 2 shows that non-stimulated ECs had undetectable
iNOS protein with and without ascorbate pretreatment
(lanes/bars 1 and 5). LPS alone had negligible e¡ect on
iNOS induction (lanes/bars 2 vs. 1), whereas IFNQ alone
induced a substantial amount of iNOS protein (lanes/bars 3
vs. 1). Nevertheless the combination of LPS+IFNQ (i.e. the
optimal concentration for iNOS induction in ECs [14])
caused even greater induction of iNOS (lanes/bars 4 vs. 1).
However, the induction of iNOS by IFNQ alone or LPS+IFNQ
was attenuated in ECs that had been loaded with ascorbate
(lanes/bars 7 vs. 3 and 8 vs. 4). To con¢rm the results with
ascorbate, we used the ascorbate derivative ascorbate-2-phos-
phate. Because the 2,3-enediol moiety of ascorbate is blocked
with phosphate, ascorbate-2-phosphate is resistant to oxida-
tion and generates less oxygen radicals in the medium than
does extracellular ascorbate [15]. As shown in Fig. 3, pre-
treatment of ECs with ascorbate-2-phosphate decreased the
iNOS protein induced by LPS+IFNQ (lanes/bars 4 vs. 2) to
the same extent as did ascorbate (lanes/bars 4 vs. 3). Co-
administration of superoxide dismutase (SOD), the superox-
ide anion scavenger, diminished LPS+IFNQ-induced iNOS
expression (lanes/bars 5 vs. 2) to the same extent as did
ascorbate preloading (lanes/bars 5 vs. 3). Ascorbate alone
did not induce iNOS protein expression and did not a¡ect
cell viability as assessed by Trypan blue exclusion assay (data
not shown).
3.3. Ascorbate acts through decreasing intracellular oxidant
stress
Fig. 4 shows that ascorbate pretreatment signi¢cantly de-
creased the levels of intracellular oxidants in both non-stimu-
lated and LPS+IFNQ-stimulated cells (bars 2 vs. 1 and 4 vs. 3
in Fig. 4B). The decrease observed in the LPS+IFNQ-stimu-
lated ECs was associated with marked inhibition of iNOS
expression (lanes 4 vs. 3 in Fig. 4A). To identify the oxidants
that ascorbate targets, LPS+IFNQ-treated ECs were exposed
to exogenous superoxide generated by xanthine oxidase/xan-
thine (XO/X) plus catalase. Since the XO/X system also makes
hydrogen peroxide and hydroxyl radical [16], we added cata-
lase to reduce hydrogen peroxide and to block hydroxyl rad-
ical generation. Superoxide caused a signi¢cant increase of
intracellular oxidant stress (bars 5 vs. 3 in Fig. 4B) that was
paralleled by an enhanced iNOS expression (lanes 5 vs. 3 in
Fig. 4A). Moreover, superoxide abolished the e¡ect of pre-
loaded ascorbate on iNOS induction (lanes 6 vs. 4 in Fig. 4A)
by increasing the intracellular oxidant stress (bars 6 vs. 4 in
Fig. 4B). Superoxide alone did not induce iNOS expression in
ECs that had not been stimulated by LPS+IFNQ (data not
shown). These results indicate that ascorbate prevents iNOS
induction by scavenging superoxide, since its e¡ect was abro-
gated by excess superoxide.
3.4. Ascorbate e¡ect is not mediated by NO
‘iNOS induction in ECs can be inhibited by NO donor [9].
Therefore, we investigated whether scavenging of superoxide
by ascorbate increases endogenous NO to levels that sup-
press iNOS induction. As shown in Fig. 5, ascorbate pre-
Fig. 1. Intracellular ascorbate concentration in ECs after ascorbate
pretreatment. ECs were incubated with vehicle or 100 WM ascorbate
for 24 h, then treated in ascorbate-free medium with LPS (25 ng/
ml)+IFNQ (100 U/ml) or without LPS+IFNQ for the indicated times.
Ascorbate concentrations in the cells were assayed by acidic extrac-
tion and HPLC with electrochemical detection. Shown are mean-
s S S.E.M. for three separate experiments with duplicate determina-
tions in each. * indicates P6 0.05 compared to both the vehicle-
treated and ascorbate-treated groups at 0 h.
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treatment decreased iNOS expression and NOx formation in
ECs stimulated by LPS+IFNQ (lanes/bars 4 vs. 3). The NOS
inhibitor N-nitro-L-arginine methyl ester (L-NAME) pre-
vented NOx formation (bars 5 vs. 3) but enhanced iNOS ex-
pression (lanes 5 vs. 3). However, the inhibition of iNOS ex-
pression by ascorbate occurred even in the presence of
L-NAME (i.e. in the absence of endogenous NO) (lanes/
bars 6 vs. 5) as well as in the presence of oxyhemoglobin
(10 WM) that scavenges NO (data not shown). Therefore,
our results are not consistent with the hypothesis that inhibi-
tion of iNOS expression by ascorbate is mediated by negative
feedback of NO.
3.5. Ascorbate modulation of IRF-1 and NFUB
Since regulation of iNOS expression occurs mainly at the
transcriptional level [7,8] and IRF-1 and NFUB are important
in iNOS gene activation [17,18], the current study examined
the e¡ect of ascorbate on activation of both these transcrip-
tion factors. IFNQ or LPS+IFNQ, but not LPS alone, caused a
signi¢cant increase in activation of IRF-1 (lanes/bars 3,4 vs. 1
in Fig. 6). This activation was associated with increased iNOS
expression (lanes/bars 3,4 vs. 1 in Fig. 2). A comparison of
lanes/bars 7,8 against lanes/bars 3,4, respectively, in Fig. 6,
reveals much less IRF-1 activation in ascorbate-loaded cells,
suggesting that ascorbate reduces iNOS induction (lanes/bars
7,8 in Fig. 2) at the IRF-1 level.
NFUB was activated after LPS+IFNQ exposure (lanes/bars 1
vs. 4 in Fig. 7). This activation was consistent with iNOS
protein expression (lanes/bars 4 vs. 1 in Fig. 2). However,
NFUB was also activated after LPS alone (lanes/bars 2 vs. 1
in Fig. 7) without concomitant iNOS expression (lanes/bars 2
vs. 1 in Fig. 2). Thus, NFUB activation was not su⁄cient for
iNOS induction. Ascorbate had no e¡ect on NFUB activation
(lanes/bars 6,8 vs. 2,4 in Fig. 7). Therefore, the modulating
e¡ect of ascorbate on iNOS induction (Fig. 2) was unlikely to
be mediated at the NFUB level.
4. Discussion
Since oxidation of ascorbate in culture medium produces
hydrogen peroxide that may a¡ect cellular function [19], we
pretreated the cells with ascorbate or ascorbate-2-phosphate
prior to LPS+INFQ exposure. Pretreatment with either form
of ascorbate inhibited the induction of iNOS protein and NOx
production by LPS+IFNQ. This e¡ect was due to an increase
in the intracellular ascorbate concentration. ECs did not con-
tain ascorbate when grown under normal culture conditions
(Fig. 1, bar 1) but accumulated it to millimolar levels when
incubated with a physiologically relevant ascorbate concentra-
tion (Fig. 1, bar 2). Although rat hepatocytes can synthesize
ascorbate [20], ECs lack this ability. The absence of intracel-
lular ascorbate may account for the oxidative stress observed
in ECs without ascorbate pretreatment (Fig. 4, bars 1 and 3).
Pretreatment with ascorbate increased the intracellular con-
centration of ascorbate (Fig. 1, bar 2) and consequently de-
creased the intracellular oxidant stress in both non-stimulated
and LPS+IFNQ-stimulated ECs (Fig. 4B). The decrease ob-
served in the LPS+IFNQ-stimulated ECs was associated with
marked inhibition of iNOS expression. These antioxidant ef-
fects of ascorbate could be abrogated by excessive superoxide,
indicating that ascorbate prevents iNOS induction by scav-
enging the intracellular superoxide. Blockade of endogenous
NO synthesis by L-NAME did not alter the e¡ect of ascor-
bate, suggesting that ascorbate does not inhibit iNOS induc-
tion by altering intracellular NO concentration. Taken togeth-
er, these observations indicate that it is the antioxidant action
of intracellular ascorbate that prevents superoxide-potentiated
iNOS induction.
The promoter region of rat iNOS gene contains binding
sites for a number of transcription factors, including NFUB
and IRF-1 [17,18]. We found no e¡ect of ascorbate on LPS-
or LPS+IFNQ-induced activation of NFUB. Similarly, ascor-
bate did not alter NFUB activation by TNFK in human aortic
ECs [21]. Other antioxidants also failed to inhibit NFUB acti-
Fig. 2. Ascorbate pretreatment inhibits iNOS induction by IFNQ
and LPS+IFNQ. ECs were incubated with vehicle or 100 WM ascor-
bate for 24 h and subsequently were incubated with vehicle, LPS
(25 ng/ml), IFNQ (100 U/ml), or LPS+IFNQ for 12 h. Shown are an
iNOS Western blot example (panel A) and the summary of protein
band intensities (panel B; expressed as percentages of values for the
LPS+IFNQ-stimulated group; meanSS.E.M. values for three experi-
ments). * indicates P6 0.05 for the e¡ect of ascorbate compared to
the relevant ascorbate-free group.
Fig. 3. Ascorbate-2-phosphate and SOD inhibit iNOS induction by
LPS+IFNQ. ECs were incubated with vehicle, 100 WM ascorbate, or
100 WM ascorbate-2-phosphate for 24 h. The cells were then incu-
bated with vehicle, LPS+IFNQ, or LPS+IFNQ plus SOD (500 U/ml)
for 12 h. Shown are an iNOS Western blot example (panel A) and
the summary of protein band intensities (panel B; expressed as per-
centages of values for the LPS+IFNQ-stimulated group; meanS
S.E.M. values for three experiments). * indicates P6 0.05 compared
to the LPS+IFNQ group.
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vation in macrophage cells stimulated by LPS or LPS+IFNQ,
but nevertheless prevented iNOS induction [22,23]. However,
the present experiments revealed that ascorbate inhibition of
iNOS induction was associated with attenuation of IRF-1
activation. This e¡ect of ascorbate in ECs is consistent with
the observation in a macrophage cell line that antioxidants
(5,7-dihydroxy£avone; 3,4-dichloroisocoumarin; N-acetyl-5-
hydroxytryptamine) blunt the DNA-binding activity of
IRF-1 that mediates iNOS induction by LPS+IFNQ [24].
While inhibiting iNOS expression, ascorbate can preserve
the activity of constitutive NOS [22,25]. This mechanism
may be important in sepsis in maintaining the physiological
functions of NO, such as preventing leukocytes’ adherence to
Fig. 4. Superoxide abolishes the e¡ect of ascorbate pretreatment on
iNOS induction by LPS+IFNQ. ECs were incubated for 24 h with
vehicle or 100 WM ascorbate. Next they were incubated with vehicle,
LPS+IFNQ, or the combination of LPS+IFNQ, XO/X (10 mU per
ml/100 WM) and catalase (CAT; 5000 U/ml), either for 12 h to in-
duce iNOS protein or for 6 h in the presence of 20 WM DHR123.
The oxidized DHR123 was measured by £uorescence spectropho-
tometry. Shown are an iNOS Western blot example of three experi-
ments (panel A) and the summary of DHR123 £uorescence data
(panel B; meanSS.E.M. values for four experiments with triplicate
determinations in each). * indicates P6 0.05 compared to the con-
trol group that did not receive ascorbate, superoxide or LPS+IFNQ.
Fig. 5. Ascorbate inhibition of iNOS induction is not mediated by
NO. ECs were incubated for 24 h with vehicle or 100 WM ascor-
bate. Next, they were incubated for 12 h with vehicle, LPS+IFNQ,
or the combination of LPS+IFNQ and L-NAME (5 mM). NOx in
the culture medium was measured by Griess reaction. Shown are an
iNOS Western blot example of three experiments (panel A) and the
summary of NOx levels (panel B; meanSS.E.M. values for 4 ex-
periments with duplicate determinations in each).
Fig. 6. E¡ect of ascorbate on LPS, IFNQ, or LPS+IFNQ-stimulated
activation of IRF-1. ECs were incubated for 24 h with vehicle or
100 WM ascorbate. Subsequently they were incubated with vehicle,
LPS, IFNQ, or LPS+IFNQ for 12 h. Nuclear proteins were extracted
and reacted with speci¢c oligonucleotides. Shown are an IRF-1
EMSA example (panel A) and the summary of IRF-1-speci¢c band
intensities (panel B; expressed as percentages of values for the
LPS+IFNQ-stimulated group; meanSS.E.M. values for three experi-
ments). * indicates P6 0.05 for the e¡ect of IFNQ or LPS+IFNQ
compared to the non-treated group (bar 1); # indicates P6 0.05 for
the e¡ect of ascorbate compared to the relevant ascorbate-free
group.
Fig. 7. E¡ect of ascorbate on LPS, IFNQ, or LPS+IFNQ-stimulated
activation of NFUB. ECs were incubated for 24 h with vehicle or
100 WM ascorbate. Subsequently they were treated with vehicle,
LPS, IFNQ, or LPS+IFNQ for 12 h. Nuclear proteins were extracted
and reacted with speci¢c oligonucleotides. Shown are a NFUB
EMSA example (panel A) and the summary of NFUB-speci¢c band
intensities (panel B; expressed as percentages of values for the
LPS+IFNQ-stimulated group; meanSS.E.M. values for 3 experi-
ments). Ascorbate had no e¡ect on NFUB levels in any of the treat-
ment groups.
FEBS 26140 27-5-02
F. Wu et al./FEBS Letters 520 (2002) 122^126 125
endothelium [26]. In addition, ascorbate may prevent direct
injury by oxidants that have been implicated in the patho-
genesis of sepsis [27,28]. Thus, ascorbate treatment may be a
new way to selectively inhibit iNOS induction for sepsis ther-
apy. We conclude that pretreatment of microvascular ECs
with ascorbate blunts iNOS induction by LPS+IFNQ by re-
ducing intracellular oxidant stress.
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